Pharmacologic treatments for covid-19 patients

Analyses are updated every two weeks

Methods

Treatment comparisons

Create and download your forest plots with the most up-to-date data here Forest plots

Access the forest plots for the 292 treatment comparisons .

General characteristics of primary studies

Page: 1 / Sorted by: Most recent ↓
Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
New
ChiCTR2000029972
Huang L, medRxiv (2021)
Full text
Commentary
Commentary
Public/non profit

SWD

Standard care

RCT Patients with confirmed COVID-19 (mild-moderate) admitted to a single center in China N=50
Some concerns
Details

Full description

New
PACTR202108891693522
Babalola O, J Infect Dis Epidemi (2021)
Full text
Commentary
Commentary
Commentary
Public/non profit

Hydroxychloroquine+iverme

Ivermectin

RCT Patients with confirmed COVID-19 (mild-critical) admitted to a single center in Nigeria. N=61
High
Details

Full description

New
NCT04397757
PennCCP2
Bar KJ, J Clin Invest (2021)
Full text
Commentary
Public/non profit

Convalescent plasma

Standard care

RCT Patients with confirmed COVID-19 (mild-severe) admitted to 2 centers in the USA. N=80
Some concerns
Details

Full description

New
NCT04518410
ACTIV-2/A5401
Chew K (B), medRxiv (2021)
Full text
Commentary
Commentary
Mixed

Bamlanivimab 700 mg

Placebo

RCT Outpatients with confirmed COVID-19 (mild) treated at 38 centers in the USA N=222
Some concerns
Details

Full description

New
CTRI/2020/09/027535
Ramachandran R, Int. J. Infect. Dis. (2021)
Full text
00872-9/fulltext Commentary
Public/non profit

Umifenovir

Standard care

RCT In- and outpatients with confirmed COVID-19 (asymptomatic-mild-moderate) treated or admitted by 3 centers in India N=132
Some concerns
Details

Full description

New
IRCT20120703010178N20
Kharazmi AB, Immun Inflamm Dis (2021)
Full text
Commentary
Private

Anakinra

Standard care

RCT Patients with confirmed COVID-19 (moderate-critical) admitted to a single center in Iran. N=30
High
Details

Full description

New
NCT04518410
ACTIV-2/A5401
Chew K (A), medRxiv (2021)
Full text
Commentary
Commentary
Mixed

Bamlanivimab 7000 mg

Placebo

RCT Outpatients with confirmed COVID-19 (mild) treated at 38 centers in the USA N=97
Some concerns
Details

Full description

NCT04435184
Leucker T, JACC (2021)
Full text
Commentary
Private

Crizanlizumab

Placebo

RCT Patients with confirmed COVID-19 (mild-moderate) admitted to 3 centers in the USA N=54
Some concerns
Details

Full description

NCT04501978
ACTIV-3
Self WH, Lancet Infect Dis (2021)
Full text
Commentary
(21)00762-3/fulltext Commentary
Mixed

Sotrovimab

BRII-196/BRII-198

Sotrovimab

Placebo

Placebo

BRII-196/BRII-198

RCT Patients with confirmed COVID-19 (mild-moderate) admitted to 43 centres in Denmark, Poland, Switzerland, and USA N=546
Low
Details

Full description

NCT04501952; EudraCT 2020-003510-12.
Gottlieb RL, N Engl J Med (2021)
Full text
Commentary
Commentary
Private

Remdesivir

Placebo

RCT Outpatients with confirmed COVID-19 (mild) treated at 64 centers in Denmark, Spain, UK and USA. N=584
Some concerns
Details

Full description